Real-world treatment patterns, outcomes, and healthcare resource use for myelofibrosis in Brazil: Subgroup analysis of the METER study
4 affiliations
- 1Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, (HCFMUSP), São Paulo, SP, Brazil; Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, SP, Brazil
- 2AbbVie, Brazil; Corresponding author at: Av. Jornalista Roberto Marinho, 85 / 7° Andar - Brooklin Novo, São Paulo, 04576-010, SP, Brazil.
- 3AbbVie International, United States of America
- 4Albert Einstein Israelita Hospital, São Paulo, Brazil
Abstract
Background: The METER study (NCT05444972) described real-world treatment patterns and outcomes for myelofibrosis across 14 countries. Given the potential regional variability, the present analysis evaluates the Brazilian cohort within METER to investigate local treatment approaches and patient results. Methods: This subanalysis of the METER study included all patients enrolled in Brazil, based on the same eligibility criteria as in the global study. The primary objective was to describe real-world treatment patterns for myelofibrosis. Main results: Of 50 eligible patients enrolled in Brazil, 37 (74%) presented with primary myelofibrosis. At diagnosis, nine (20.9%) individuals had high-risk and 14 (32.6%) intermediate-2 risk disease, mostly using the Dynamic International Prognostic Scoring System (DIPSS) criteria. Among patients with available data (n = 18), 50% had a high-risk mutation at diagnosis. Hydroxyurea was the most frequent initial therapy (n = 32; 64%), followed by ruxolitinib (n = 12; 24%). A total of 23 patients (46%) had discontinuation or change of initial therapy, with a median overall duration of first-line treatment of 29.9 months (95% confidence interval: 21.5 to not estimable). The median overall survival from index date was 45.5 months (95% confidence interval: 28.5 to not estimable), with 1- and 2-year survival rates of 87.3% and 74.7%, respectively. Conclusion: The treatment patterns in Brazil reflect insufficient access to novel agents. Whether the shorter observed median overall survival compared with the overall METER study is a consequence of insufficient access to treatment or of different biological features warrants further investigation.
Related
- Real-World Treatment Patterns, Healthcare Resource Use, and Costs in Patients with Follicular Lymphoma, Waldenström Macroglobulinemia, and Marginal Zone Lymphoma: A Claims-Based Study in the USA
- Treatment patterns and outcomes of pediatric rhabdomyosarcoma in a resource-limited setting: A retrospective study from a tertiary hospital in Ethiopia
- Thirty-day clinical outcomes, early recovery, and healthcare resource use after planned ambulatory vs. conventional inpatient laparoscopic cholecystectomy: a propensity-score overlap-weighted retrospective cohort study
- Injury Mechanisms, Management Patterns, and Early Outcomes After Surgical Treatment of Hand Trauma: A Franco-Romanian Two-Center Cohort Study
- Follow‐Up and Outcomes After Thermal Ablation Treatment Among HIV ‐Infected Women From Resource‐Limited Countries With Positive HPV ‐Based Screening: Results of the AIMA ‐ CC Cohort ( ANRS 12375)
BibTeX
@article{seguro2026realworld,
title = {{Real-world treatment patterns, outcomes, and healthcare resource use for myelofibrosis in Brazil: Subgroup analysis of the METER study}},
author = {Fernanda Seguro and Ingrid Pereira and Maria Duran and Nelson Hamerschlak},
journal = {Hematology, Transfusion and Cell Therapy},
year = {2026},
month = oct,
doi = {10.1016/j.htct.2026.108551},
url = {https://doi.org/10.1016/j.htct.2026.108551},
note = {CC BY},
}
RIS
TY - JOUR
TI - Real-world treatment patterns, outcomes, and healthcare resource use for myelofibrosis in Brazil: Subgroup analysis of the METER study
AU - Fernanda Seguro
AU - Ingrid Pereira
AU - Maria Duran
AU - Nelson Hamerschlak
PY - 2026
DA - 2026/10/31
JO - Hematology, Transfusion and Cell Therapy
DO - 10.1016/j.htct.2026.108551
UR - https://doi.org/10.1016/j.htct.2026.108551
AB - Background: The METER study (NCT05444972) described real-world treatment patterns and outcomes for myelofibrosis across 14 countries. Given the potential regional variability, the present analysis evaluates the Brazilian cohort within METER to investigate local treatment approaches and patient results. Methods: This subanalysis of the METER study included all patients enrolled in Brazil, based on the same eligibility criteria as in the global study. The primary objective was to describe real-world treatment patterns for myelofibrosis. Main results: Of 50 eligible patients enrolled in Brazil, 37 (74%) presented with primary myelofibrosis. At diagnosis, nine (20.9%) individuals had high-risk and 14 (32.6%) intermediate-2 risk disease, mostly using the Dynamic International Prognostic Scoring System (DIPSS) criteria. Among patients with available data (n = 18), 50% had a high-risk mutation at diagnosis. Hydroxyurea was the most frequent initial therapy (n = 32; 64%), followed by ruxolitinib (n = 12; 24%). A total of 23 patients (46%) had discontinuation or change of initial therapy, with a median overall duration of first-line treatment of 29.9 months (95% confidence interval: 21.5 to not estimable). The median overall survival from index date was 45.5 months (95% confidence interval: 28.5 to not estimable), with 1- and 2-year survival rates of 87.3% and 74.7%, respectively. Conclusion: The treatment patterns in Brazil reflect insufficient access to novel agents. Whether the shorter observed median overall survival compared with the overall METER study is a consequence of insufficient access to treatment or of different biological features warrants further investigation.
SN - 2531-1379
SN - 2531-1387
ER -